Global Information
회사소개 | 문의 | 비교리스트

빌름스 종양(신아세포종) : 파이프라인 리뷰

Wilms´ Tumor (Nephroblastoma) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 410978
페이지 정보 영문 54 Pages
가격
US $ 2,000 ₩ 2,408,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,816,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,224,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


빌름스 종양(신아세포종) : 파이프라인 리뷰 Wilms´ Tumor (Nephroblastoma) - Pipeline Review, H2 2016
발행일 : 2016년 12월 페이지 정보 : 영문 54 Pages

빌름스 종양(신아세포종)은 아동에게 전형적으로 생기는 신장암이며, 드물게는 어른에게도 발병합니다. 빌름스 종양은 보통 한쪽 신장에 발생하는데, 양쪽 신장에서 발견되기도 합니다. 전형적인 증상은 복부 이상비대, 복통, 열, 오심 및 구토, 혈뇨(20% 정도) 등이며, 고혈압증이 나타나는 경우도 있습니다.

빌름스 종양(신아세포종) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등을 전해드립니다.

서론

  • 조사 범위

빌름스 종양(신아세포종) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 임상시험 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발 참여 기업

  • Exelixis Inc
  • NanoSmart Pharmaceuticals Inc
  • Recombio SL
  • Selvita SA

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

약제 프로파일

  • cabozantinib s-malate
  • Cellular Immunotherapy for Oncology
  • Monoclonal Antibody Conjugate for Wilms' Tumor
  • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology
  • racotumomab
  • SEL-12034

휴지 상태인 프로젝트

부록

도표

LSH 17.01.31

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides an overview of the Wilms' Tumor (Nephroblastoma) (Oncology) pipeline landscape.

Wilms' tumor or nephroblastoma is cancer of the kidneys that typically occurs in children, rarely in adults. Its common name is an eponym.Wilms' tumor is a rare kidney cancer that primarily affects children.Wilms' tumor most often occurs in just one kidney, though it can sometimes be found in both kidneys at the same time. Typical symptoms are: an abnormally large abdomen, abdominal pain, fever, nausea and vomiting, blood in the urine (in about 20% of cases) and high blood pressure in some cases.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Wilms' Tumor (Nephroblastoma) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Wilms' Tumor (Nephroblastoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Wilms' Tumor (Nephroblastoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Wilms' Tumor (Nephroblastoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Wilms' Tumor (Nephroblastoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Wilms' Tumor (Nephroblastoma) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Wilms' Tumor (Nephroblastoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Wilms' Tumor (Nephroblastoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wilms' Tumor (Nephroblastoma) Overview
  • Therapeutics Development
    • Pipeline Products for Wilms' Tumor (Nephroblastoma) - Overview
    • Pipeline Products for Wilms' Tumor (Nephroblastoma) - Comparative Analysis
  • Wilms' Tumor (Nephroblastoma) - Therapeutics under Development by Companies
  • Wilms' Tumor (Nephroblastoma) - Therapeutics under Investigation by Universities/Institutes
  • Wilms' Tumor (Nephroblastoma) - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Wilms' Tumor (Nephroblastoma) - Products under Development by Companies
  • Wilms' Tumor (Nephroblastoma) - Products under Investigation by Universities/Institutes
  • Wilms' Tumor (Nephroblastoma) - Companies Involved in Therapeutics Development
    • Exelixis Inc
    • NanoSmart Pharmaceuticals Inc
    • Recombio SL
    • Selvita SA
  • Wilms' Tumor (Nephroblastoma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • cabozantinib s-malate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Wilms' Tumor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • racotumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-12034 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Wilms' Tumor (Nephroblastoma) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016
  • Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Exelixis Inc, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by NanoSmart Pharmaceuticals Inc, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Recombio SL, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Pipeline by Selvita SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Wilms' Tumor (Nephroblastoma) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Wilms' Tumor (Nephroblastoma), H2 2016
  • Number of Products under Development for Wilms' Tumor (Nephroblastoma) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top
전화 문의
F A Q